Suven Discovery Scientific Presentations in 2008

International Conference on Alzheimer's Disease (ICAD)

July 26 - 31, 2008, Chicago, USA

1. SUVN-502: A potent, selective, brain penetrant and orally active 5-HT_6 receptor antagonist for the symptomatic treatment of Alzheimer's disease.

   R. Nirogi, *et al.,*

2. 5-HT_6 receptor antagonist SUVN-502 enhances acetylcholine and glutamate in rat ventral hippocampus and frontal cortex – A microdialysis study.

   G. Bhyrapuneni, *et al.,*

3. Dual blockade of cholinergic and glutamatergic neural system induced memory impairment in rats – A model for Alzheimer's disease

   P. Jayarajan, *et al.,*

American Chemical Society (ACS)

August 17 - 21, 2008, Philadelphia, USA

4. Novel centrally acting 5-HT_6 receptor ligands as potential anti-obesity agents.

   R. Nirogi, *et al.,*

5. Novel tetracyclic tryptamine derivatives with rigidized side chain as potential 5-HT_6 receptor ligands.

   R. Kambhampati, *et al.,*

6. Novel conformationally restricted 3-aminoalkoxy indole derivatives as 5-HT_6 receptor ligands.

   A. Daulatabad, *et al.,*

7. Piperidinyloxy aryl sufonamides: New chemical class of selective 5-HT_6 receptor antagonists as potential anti-obesity agents.

A. Shinde, *et al.,*

8. Novel route for the synthesis of 3-indolylox ethyl derivatives.

   R. Kambhampati, *et al.,*

9. Synthesis of 2-amino methyl-3-halo indole derivatives as serotonin receptor ligands using Vilsmeier reaction..

   R. Nirogi, *et al.,*

Society For Neuroscience (SFN)

November 15-19, 2008, Washington, DC, USA

10. SB-399885 in animal models of predictive antidepressant activity.

    P. Jayarajan*, D. Shanmuganathan, R. Abraham, et. al.*

11. Effect of age of laboratory rodents on neurobiological experiments.

    R. Abraham*, P, Jayarajan, M. Dokania et. al.,*

12. Effect of SUVN-502 in animal models of working memory.

    R. Nirogi*, R. Abraham, A. Bokare et. al.,*

13. 5-HT_6 antagonists in animal models of feeding behavior.

    A. Bokare*, D. Shanmuganathan, P. Jayarajan et. al.,*

14. SUVN-51005 - A potent 5-HT_6 antagonist in animal models of obesity.

    D. Shanmuganathan*, S. Koul, R. Abraham et. al.,*

15. Establishment of reporter gene-based assay for screening 5-HT_6 receptor ligands.

    I. Ahmad, *V. Mekala, M. Chillakur et. al.,*

16. 5-HT_6 receptor antagonist SUVN-502 selectively enhances acetylcholine and glutamate levels in the rat ventral hippocampus and frontal cortex.

    G. Bhyrapuneni*, N. Muddana, V. Saralaya et. al.,*

17. SUVN-507 - A potent 5-HT_6 receptor antagonist enhances extracellular levels of glutamate in rat frontal cortex.

***N. Muddana**, V. Benade, R. Saralaya, et. al.,*

AAPS Annual Meeting & Exposition 2008

November 16-20, 2008, Atlanta, GA, USA

18. Simultaneous quantification of efavirenz, emtricitabine and tenofovir in human plasma by LC-MS-MS.

***P. Komarneni** et. al.,*

19. Pharmacokinetic and pharmacodynamic correlation of Aripiprazole in alcohol addicted rats.

***P. Jayarajan** et. al.,*

20. Validation of whole body and head out plethysmograph using respiratory stimulant and depressant.

***D. Shanmuganathan** et. al.,*

21. Determination of plasma free fraction of drugs using rapid equilibrium dialysis.

***S. Irappanavar** et. al.,*

22. Comparison of IC_{50} values from human liver microsomes and supersomes.

***R. Ponnamaneni** et. al.,*

23. Design and synthesis of thieno[2,3-d]pyrimidin-2-yl methyl piperazines as potential antagonists at 5-HT_6 receptors.

***R. Kambhampati** et. al.,*

24. Design and synthesis of 2-arylsulfonylmethyl-3-piperazinylmethyl indole derivatives as novel 5-HT_6 receptor ligands.

***A. Shinde** et. al.,*